April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Normative Comparison of Patient-Reported Outcomes in Patients With Noninfectious Intermediate or Posterior Uveitis
Author Affiliations & Notes
  • Rupali K. Naik
    Global Health Outcomes,
    Allergan, Irvine, California
  • Careen Y. Lowder
    Cole Eye Institute, The Cleveland Clinic, Cleveland, Ohio
  • Sue Lightman
    UCL/Institute of Ophthalmology, Moorfields Eye Hospital, London, United Kingdom
  • Anne M. Rentz
    Center for Health Outcomes Research, United BioSource Corporation, Cologne, Germany
  • Jonathan Kowalski
    Glbl Hlth Outcomes Strat Res,
    Allergan, Irvine, California
  • C. Stephen Foster
    Ophthalmology, Ocular Immunology and Uveitis Foundation, Cambridge, Massachusetts
  • Rubens Belfort, Jr.
    Vision Institute Dept. of Ophthalmology, Federal Univ of São Paulo, Sao Paulo, Brazil
  • Dennis Revicki
    United BioSource Corporation, Bethesda, Maryland
  • Scott M. Whitcup
    R & D,
    Allergan, Irvine, California
  • Footnotes
    Commercial Relationships  Rupali K. Naik, Allergan (E); Careen Y. Lowder, Allergan (F); Sue Lightman, Allergan (C); Anne M. Rentz, United Biosource (E); Jonathan Kowalski, Allergan (E); C. Stephen Foster, None; Rubens Belfort, Jr., Allergan, Alcon (C); Dennis Revicki, United Biosource (E); Scott M. Whitcup, Allergan (E)
  • Footnotes
    Support  Allergan, Inc.
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 2729. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rupali K. Naik, Careen Y. Lowder, Sue Lightman, Anne M. Rentz, Jonathan Kowalski, C. Stephen Foster, Rubens Belfort, Jr., Dennis Revicki, Scott M. Whitcup; Normative Comparison of Patient-Reported Outcomes in Patients With Noninfectious Intermediate or Posterior Uveitis. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2729.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To compare vision-related functioning and health-related quality of life (HRQL) of patients with noninfectious intermediate or posterior uveitis to the US general population and normal-vision reference groups.

Methods: : Secondary analysis of HRQL data administered at baseline to patients with noninfectious intermediate or posterior uveitis, participating in a 26-week, multicenter, masked, randomized, sham-controlled trial of dexamethasone intravitreal implant (n = 224). PRO measures included the NEI VFQ-25, SF-36®, SF-6D, and EQ-5D. SF-36 and SF-6D scores were compared to US general population samples using the National Health Measurement Study (n = 3844) and Medical Expenditure Panel Survey (n = 955) data. EQ-5D scores were compared to the MEPS data. The VFQ-25 data were compared with published VFQ-25 scores from a normal-vision reference group (n = 122).

Results: : Uveitis patients had significantly more impaired SF-36 Mental Component Summary scores and SF-6D scores compared to a general US population sample (P < .001). No significant differences were found for the Physical Component Summary scores and EQ-5D scores between the uveitis and general population samples. Based on the VFQ-25, compared with a normal-vision population, the uveitis sample had clinically significant impairments across all VFQ-25 subscales and the composite score, with all subscale score differences exceeding 10 points (P < .001).

Conclusions: : Compared to the US general population and normal-vision reference groups, noninfectious intermediate or posterior uveitis results in meaningful reductions in mental health outcomes, HRQL, and vision-related functioning.

Clinical Trial: : http://www.clinicaltrials.gov 00333814

Keywords: uveitis-clinical/animal model • quality of life 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.